These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

829 related articles for article (PubMed ID: 27139805)

  • 1. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
    Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.
    Heyderman RS; Madhi SA; French N; Cutland C; Ngwira B; Kayambo D; Mboizi R; Koen A; Jose L; Olugbosi M; Wittke F; Slobod K; Dull PM
    Lancet Infect Dis; 2016 May; 16(5):546-555. PubMed ID: 26869376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial.
    Absalon J; Segall N; Block SL; Center KJ; Scully IL; Giardina PC; Peterson J; Watson WJ; Gruber WC; Jansen KU; Peng Y; Munson S; Pavliakova D; Scott DA; Anderson AS
    Lancet Infect Dis; 2021 Feb; 21(2):263-274. PubMed ID: 32891191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women.
    Leroux-Roels G; Maes C; Willekens J; De Boever F; de Rooij R; Martell L; Bedell L; Wittke F; Slobod K; Dull P
    Vaccine; 2016 Apr; 34(15):1786-91. PubMed ID: 26928074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy.
    Madhi SA; Koen A; Cutland CL; Jose L; Govender N; Wittke F; Olugbosi M; Sobanjo-Ter Meulen A; Baker S; Dull PM; Narasimhan V; Slobod K
    Clin Infect Dis; 2017 Nov; 65(11):1897-1904. PubMed ID: 29029127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial.
    Swamy GK; Metz TD; Edwards KM; Soper DE; Beigi RH; Campbell JD; Grassano L; Buffi G; Dreisbach A; Margarit I; Karsten A; Henry O; Lattanzi M; Bebia Z
    Vaccine; 2020 Oct; 38(44):6930-6940. PubMed ID: 32883555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial.
    Beran J; Leroux-Roels G; Van Damme P; de Hoon J; Vandermeulen C; Al-Ibrahim M; Johnson C; Peterson J; Baker S; Seidl C; Dreisbach A; Karsten A; Corsaro B; Henry O; Lattanzi M; Bebia Z
    Vaccine; 2020 Apr; 38(16):3227-3234. PubMed ID: 32169390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4-6 Years After a First Dose: Results From a Phase 2 Trial.
    Leroux-Roels G; Bebia Z; Maes C; Aerssens A; De Boever F; Grassano L; Buffi G; Margarit I; Karsten A; Cho S; Slobod K; Corsaro B; Henry O
    Clin Infect Dis; 2020 Jun; 70(12):2570-2579. PubMed ID: 31394574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
    Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
    Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies.
    Bézay N; Wagner L; Kadlecek V; Obersriebnig M; Wressnigg N; Hochreiter R; Schneider M; Dubischar K; Derhaschnig U; Klingler A; Larcher-Senn J; Eder-Lingelbach S; Bender W
    Lancet Infect Dis; 2024 Sep; 24(9):1045-1058. PubMed ID: 38830375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal Immunization With an Investigational Trivalent Group B Streptococcal Vaccine: A Randomized Controlled Trial.
    Donders GG; Halperin SA; Devlieger R; Baker S; Forte P; Wittke F; Slobod KS; Dull PM
    Obstet Gynecol; 2016 Feb; 127(2):213-21. PubMed ID: 26942345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
    Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
    Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women.
    Fabbrini M; Rigat F; Tuscano G; Chiarot E; Donders G; Devlieger R; Filippini S; Frigimelica E; Forte P; Wittke F; Halperin SA; Slobod K; Grandi G; Margarit I
    J Infect; 2018 May; 76(5):449-456. PubMed ID: 29374589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA; Capeding MR; Bavdekar A; Marchetti E; Ariff S; Soofi SB; Anemona A; Habib MA; Alberto E; Juvekar S; Khan RM; Marhaba R; Ali N; Malubay N; Kawade A; Saul A; Martin LB; Podda A
    Lancet Infect Dis; 2014 Feb; 14(2):119-29. PubMed ID: 24290843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
    Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
    Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.